Minocycline Plus Amiodarone Versus Amiodarone Alone for the Prevention of Atrial Fibrillation After Cardiac Surgery (MINA)
May 01, 2020
Abdallah Alameddine, MD
Baystate Medical Center, 759 Chestnut St, Springfield, MA
Postoperative atrial fibrillation (POAF) is a common complication after heart surgery. Amiodarone is the drug of choice to treat POAF. Inflammation is considered one of underlying factor for POAF. Minocycline is an antibiotic with anti-inflammatory properties. This is a valuable interventional trial that would affect the method in which the investigators practice.
Eligibility criteria includes all non-congenital cardiac operations are included:
- Coronary artery bypass graft (CABG),
- valve repair/replacement, or
- combination of CABG and heart valve operations.
- Prior (within 6 months) or current PAF or flutter,
- prior cerebrovascular event,
- cardiogenic shock or resuscitation,
- evidence of hepatic or renal dysfunctions (i.e., an alanine aminotransferase level that is ≥ twice the upper limit of the normal range, or either a serum creatinine level that is ≥ 2.0 mg/dL or need for preoperative dialysis),
- thyrotoxicosis (excess of thyroid hormone in the body),
- severe COPD (FEV1/FVC <70%),
- recent history of drug or alcohol abuse, and
- intolerance to tetracycline or amiodarone.
Finally, because a core scientific basis of the trial concerned the role of underlying atrial tissue inflammatory activity, patients with inflammatory conditions such as lupus, severe arthritis, thyroiditis or inflammatory bowel disease are excluded; as are patients taking preoperative immunosuppressant agents, long-term oral corticosteroids, or estrogen replacement; and a newly diagnosed cancer (<5 years).
May 2020 - January 2022
Interventional (Clinical Trial)
Barbara Burkott, BN, BSNCCRP
(413) 794-0000 ext. 1305